Real‑world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma

  • Authors:
    • Leila Khoja
    • Eshetu G. Atenafu
    • Qian Ye
    • Craig Gedye
    • Maryanne Chappell
    • David Hogg
    • Marcus O. Butler
    • Anthony M. Joshua
  • View Affiliations

  • Published online on: December 31, 2015     https://doi.org/10.3892/ol.2015.4069
  • Pages: 1581-1585
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Approved by the Food and Drug Administration in 2011, the anti‑cytotoxic T‑lymphocyte‑associated protein 4 checkpoint inhibitor ipilimumab has delivered a survival benefit of ≥3 years in a subset of metastatic melanoma patients. After participating in the registration trial, patients were treated with this agent in routine practice. Toxicity and efficacy of agents in “real world” settings may differ from trials. The present study aimed to evaluate, with respect to toxicity and outcome, all patients treated with ipilimumab to date at the Princess Margaret Hospital (Toronto, Canada). Patients treated with ipilimumab between 2008 and 2013 were identified, and patient characteristics (age, gender, tumour burden, oncogenic mutation status, number of treatments received and toxicities from treatment) were collected. Progression‑free survival (PFS) and overall survival (OS) were calculated from the commencement of ipilimumab treatment. Associations between clinical characteristics and outcome or toxicity were assessed. Between 2008 and 2013, 129 patients with metastatic cutaneous melanoma were treated. Since, during this period, ipilimumab was approved in the second line setting, ipilimumab was delivered in the second or subsequent line in all patients, and 70% did not receive any further anticancer therapy. Immune‑related toxicities were observed, the onset of which varied from 1 to 162 days. The majority resolved within 6 weeks of the final treatment, with the exception of endocrinopathies and bowel related toxicity. The median PFS and OS were 2.83 and 8.44 months, respectively. No pre‑treatment factor independently predicted toxicity. The number of infusions (4 vs. ≤3) and presence of toxicity were significantly associated with superior survival. The onset of toxicity secondary to ipilimumab could occur later than previously reported. Toxicities were manageable, but required long‑term vigilance.
View Figures
View References

Related Articles

Journal Cover

February-2016
Volume 11 Issue 2

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Khoja L, Atenafu EG, Ye Q, Gedye C, Chappell M, Hogg D, Butler MO and Joshua AM: Real‑world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma. Oncol Lett 11: 1581-1585, 2016
APA
Khoja, L., Atenafu, E.G., Ye, Q., Gedye, C., Chappell, M., Hogg, D. ... Joshua, A.M. (2016). Real‑world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma. Oncology Letters, 11, 1581-1585. https://doi.org/10.3892/ol.2015.4069
MLA
Khoja, L., Atenafu, E. G., Ye, Q., Gedye, C., Chappell, M., Hogg, D., Butler, M. O., Joshua, A. M."Real‑world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma". Oncology Letters 11.2 (2016): 1581-1585.
Chicago
Khoja, L., Atenafu, E. G., Ye, Q., Gedye, C., Chappell, M., Hogg, D., Butler, M. O., Joshua, A. M."Real‑world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma". Oncology Letters 11, no. 2 (2016): 1581-1585. https://doi.org/10.3892/ol.2015.4069